NM_003072.5(SMARCA4):c.4225T>A (p.Ser1409Thr) AND Rhabdoid tumor predisposition syndrome 2

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Sep 17, 2023
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV003618839.2

Allele description [Variation Report for NM_003072.5(SMARCA4):c.4225T>A (p.Ser1409Thr)]

NM_003072.5(SMARCA4):c.4225T>A (p.Ser1409Thr)

Gene:

SMARCA4:SWI/SNF related BAF chromatin remodeling complex subunit ATPase 4 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

19p13.2

Genomic location:

Preferred name:

NM_003072.5(SMARCA4):c.4225T>A (p.Ser1409Thr)

HGVS:

NC_000019.10:g.11041361T>A
NG_011556.3:g.85430T>A
NM_001128844.3:c.4225T>A
NM_001128845.2:c.4135T>A
NM_001128846.2:c.4135T>A
NM_001128847.4:c.4126T>A
NM_001128848.2:c.4126T>A
NM_001128849.1:c.4321T>A
NM_001128849.3:c.4321T>A
NM_001374457.1:c.4126T>A
NM_001387283.1:c.4321T>A
NM_001411150.1:c.4222T>A
NM_003072.5:c.4225T>AMANE SELECT
NP_001122316.1:p.Ser1409Thr
NP_001122317.1:p.Ser1379Thr
NP_001122318.1:p.Ser1379Thr
NP_001122319.1:p.Ser1376Thr
NP_001122320.1:p.Ser1376Thr
NP_001122321.1:p.Ser1441Thr
NP_001361386.1:p.Ser1376Thr
NP_001374212.1:p.Ser1441Thr
NP_001398079.1:p.Ser1408Thr
NP_003063.2:p.Ser1409Thr
LRG_878t1:c.4225T>A
LRG_878:g.85430T>A
LRG_878p1:p.Ser1409Thr
NC_000019.9:g.11152037T>A
NR_164683.1:n.4615T>A

Protein change:

S1376T

Molecular consequence:

NM_001128844.3:c.4225T>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001128845.2:c.4135T>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001128846.2:c.4135T>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001128847.4:c.4126T>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001128848.2:c.4126T>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001128849.3:c.4321T>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001374457.1:c.4126T>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001387283.1:c.4321T>A - missense variant - [Sequence Ontology: SO:0001583]
NM_001411150.1:c.4222T>A - missense variant - [Sequence Ontology: SO:0001583]
NM_003072.5:c.4225T>A - missense variant - [Sequence Ontology: SO:0001583]
NR_164683.1:n.4615T>A - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Name:: Rhabdoid tumor predisposition syndrome 2 (RTPS2)
Identifiers:: MONDO: MONDO:0013224; MedGen: C2750074; Orphanet: 231108; Orphanet: 69077; OMIM: 613325

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV004518424	Labcorp Genetics (formerly Invitae), Labcorp	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015))	Uncertain significance (Sep 17, 2023)	germline	clinical testing	PubMed (1) [See all records that cite this PMID]

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV004518424

Labcorp Genetics (formerly Invitae), Labcorp

criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))

Uncertain significance
(Sep 17, 2023)

germline

clinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]

PMID:: 28492532
PMCID:: PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV004518424.1

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	PubMed (1)

Description

This sequence change replaces serine, which is neutral and polar, with threonine, which is neutral and polar, at codon 1441 of the SMARCA4 protein (p.Ser1441Thr). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with SMARCA4-related conditions. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SMARCA4 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Oct 13, 2024

ClinVar

Relating variation to medicine